×

Diagnosis & Therapy

Credit: F. Astier/Centre Hospitalier Régional Universitaire de Lille/Science Source
Ponesimod enters field of DMTs for relapsing forms of MS

Ponesimod enters field of DMTs for relapsing forms of MS

The Food and Drug Administration has approved once-daily oral ponesimod (Ponvory, Janssen) for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Results from a pivotal phase 3 clinical trial show the drug was associated with nearly a third fewer annual relapses, compared with the MS drug teriflunomide.

read more
Stem cell therapy for MS: Which patients is it right for?

Stem cell therapy for MS: Which patients is it right for?

Autologous hematopoietic stem cell transplant (AHSCT) shows promise for the treatment of relapsing multiple sclerosis (MS), but prospective clinical trials need to be done to confirm findings. The treatment could best be applied to patients aged under 50 years with disease duration less than 10 years, who are ineligible for disease-modifying therapies, or who have breakthrough symptoms with these treatments, such as clinical relapses or new inflammatory central nervous system lesions.

read more
Comorbidities in MS: Prevalence, Impact, and Management

Comorbidities in MS: Prevalence, Impact, and Management

Comorbidities are common in patients with multiple sclerosis (MS), can impact treatment decisions, and require a multidisciplinary approach to management, including careful attention to lifestyle issues, said Patricia Melville, RN, MSN, NP-C, MSCN, in a presentation at the virtual annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

read more
Virtual reality detects early impairment in walking balance

Virtual reality detects early impairment in walking balance

Researchers seeking simple and sensitive ways to detect walking balance impairments early on – before such impairments become clinically apparent in patients with multiple sclerosis (MS) – have reported success in the lab with the use of a virtual reality–based system that assesses one’s responses to subtle visual perturbations while walking.

read more
Growing number of MS drugs brings challenges

Growing number of MS drugs brings challenges

Major federally funded studies are underway to help neurologists better assess a growing array of multiple sclerosis treatments, including competing tablets.
But in the near term, physicians and people with MS will continue to have to make certain educated guesses when choosing medications.

read more